SLAMF7 and Miyoshi myopathy: In this review, we will specifically focus on the mAbs currently used in the treatment of MM, such as the anti-CD38 antibodies daratumumab (DARA), isatuximab (ISA) and the anti- SLAMF7 elotuzumab (ELO).